ALKS
Alkermes plc
NASDAQ · Healthcare · Biotechnology · IE
$46.10
−1.66%Aug 13, 2026, 07:27 UTC
Bank of America Corp DE reduced its stake in Alkermes plc by 9.2% during the first quarter, selling 122,254 shares, according to its 13F filing with the SEC.
Source:Aug 12, 2026, 00:00 UTC
Alkermes plc amended its credit agreement, reducing interest rate spreads and refinancing its existing tranche B term loans into new 2026 Refinancing Tranche B Term Loans, with the term loan B facility principal unchanged at $773,062,500.
Jul 28, 2026, 11:00 UTC
Alkermes plc reported its financial results for the second quarter of 2026.
Jul 13, 2026, 11:00 UTC
Alkermes plc announced results from a planned interim analysis of the long-term extension study evaluating alixorexton in adults with narcolepsy type 1 and type 2, showing sustained improvement in wakefulness.
Source:Jun 26, 2026, 17:30 UTC
Alkermes initiated a global Phase 3 program for its experimental pill alixorexton in patients with Type 2 and Type 1 narcolepsy after positive clinical data.
Source:Jun 19, 2026, 19:49 UTC
Alkermes plc reported positive phase 2 data for alixorexton in narcolepsy type 2.
Source:Jun 19, 2026, 19:49 UTC
Alkermes plc acquired Avadel Pharmaceuticals to bolster its hypersomnolence portfolio with LUMRYZ.
Source:Jun 17, 2026, 20:15 UTC
Alkermes plc announced positive results from the Vibrance-2 phase 2 study of alixorexton in adults with narcolepsy type 2 at SLEEP 2026.
Source:Jun 15, 2026, 11:00 UTC
Alkermes plc announced that its drug alixorexton received orphan drug designations from the U.S. FDA for idiopathic hypersomnia and from the European Medicines Agency for narcolepsy type 1.
Source:Jun 10, 2026, 18:09 UTC
Alkermes advances its orexin agonist program into Phase 3 clinical trials.
Source:Jun 10, 2026, 18:09 UTC
Alkermes prepares for a planned CEO transition.
Source: